Skip to main content
. 2017 Aug 4;57(9):2294–2308. doi: 10.1021/acs.jcim.7b00222

Figure 1.

Figure 1

Members of four generations of clinical steroidal (c,f) and nonsteroidal (a,b,d,e) aromatase (CYP19A1) inhibitors. First generation: aminoglutethimide (a, Cytadren, Novartis).99101 Second generation: Fadrozole (b, Afema, Novartis),99101 and Formestane (c, Lentaron, Novartis).14 Third generation: Anastrozol (d, Arimidex, AstraZeneca),102 Letrozole (e, Femara, Novartis),103105 and Exemestane (f, Aromasine, Pfizer).103